Log In
Print
BCIQ
Print
Print this Print this
 

Intranasal sumatriptan powder, OptiNose sumatriptan (AVP-825)

  Manage Alerts
Collapse Summary General Information
Company OptiNose Inc.
DescriptionLow-dose sumatriptan powder delivered intranasally using OptiNose Bi-Directional Breath Powered intranasal delivery technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat migraine with or without aura; Treat moderate to severe acute migraine pain
Regulatory Designation

U.S. - Standard Review (Treat acute migraine)

Partner

Avanir Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today